Skip to content

Latest News

Concord Biotech hits 52-week high after Jefferies initiates #39;buy#39; call; sees 19% upside

Concord Biotech hits 52-week high after Jefferies initiates #39;buy#39; call; sees 19% upside

Jefferies also prefers Concord Biotech over its peer Glenmark Life Sciences due to its superior growth profile, strong execution track record, industry-leading margins, and favourable return ratios. Read More ​ Jefferies also prefers Concord Biotech over its peer Glenmark Life Sciences… Read More »Concord Biotech hits 52-week high after Jefferies initiates #39;buy#39; call; sees 19% upside

en_USEnglish